Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE.
AMIKIN vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of mRNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic